The European Medicines Agency (EMA) has recommended the authorisation of Leqembi for the treatment of Alzheimer’s disease.

Recommended approval for Leqembi in the early treatment of Alzheimer's disease

The European Medicines Agency (EMA), through its Committee for Medicinal Products for Human Use (CHMP), has recommended the authorisation of Leqembi (lecanemab) for the treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.

This recommendation focuses on patients with one or no copies of the ApoE4 gene, who are at lower risk of amyloid-related abnormalities (ARIA), a side effect involving swelling or small brain haemorrhages.

Leqembi is an intravenous treatment given every two weeks, where patients receiving the treatment have been shown to have slower progression of Alzheimer's disease in the earliest stages.

The CHMP recommendation marks a significant advance in the treatment of Alzheimer's disease, providing a therapeutic option for early-stage patients and giving new hope for improving their quality of life.

Ace views the EMA's positive recommendation on Leqembi as a crucial milestone in the treatment of Alzheimer's disease. This breakthrough represents a tangible opportunity to improve the quality of life of people living with the disease and their families. We will continue to actively collaborate on research and the application of innovative solutions so that one day Alzheimer's will be history.

Ace:
News